Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Administration PK Study of Bomedemstat (MK-3543) in Healthy Japanese Participants
jRCT2071230096Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bomedemstat in thrombocythemia, sponsored by Merck & Co. Primary endpoint: MK-3543 pharmacokinetics. Started Jan 2024; status: completed.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on jRCT2071230096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230096.